Rochester Drug Cooperative, Inc.

CourtUnited States Bankruptcy Court, W.D. New York
DecidedMarch 22, 2021
Docket2-20-20230
StatusUnknown

This text of Rochester Drug Cooperative, Inc. (Rochester Drug Cooperative, Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, W.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rochester Drug Cooperative, Inc., (N.Y. 2021).

Opinion

UNITED STATES BANKRUPTCY COURT WESTERN DISTRICT OF NEW YORK _________________________________________

In re:

Rochester Drug Cooperative, Inc., Bankruptcy Case No. 20-20230-PRW Chapter 11

Debtor. _________________________________________

DECISION AND ORDER DENYING STAY RELIEF AS REQUESTED BY MOVANT AND GRANTING LIMITED STAY RELIEF TO PERMIT MOVANT TO SEEK TO INTERVENE IN RELATED LITIGATION PENDING IN THE DISTRICT COURT

PAUL R. WARREN, U.S.B.J. Laurence F. Doud, III was the chief executive officer of the Debtor from 1991 until April 1, 2017. (ECF No. 922 ¶ 3). Mr. Doud seeks relief from the automatic stay to obtain an advance of the costs of defending a criminal action pending against him in the Southern District of New York. (Id. ¶¶ 3-4). Specifically, Mr. Doud seeks to access insurance proceeds under a “Private Company Management Liability Insurance” policy issued by Hiscox Insurance Company, Inc. (Id. ¶ 6). The coverages available under that insurance policy are the subject of a civil action pending before the District Court, pitting the Debtor against Hiscox. That civil action pre-dates this bankruptcy case. The motion is vigorously opposed by the Debtor and the Creditors’ Committee. (ECF Nos. 948, 1174, 1238). For the reasons that follow, the relief as requested by Mr. Doud is DENIED. However, in the exercise of its discretion, the Court grants limited stay relief to Mr. Doud to allow him to seek to intervene in the civil action pending before Judge Wolford, under Rule 24 FRCP, to seek declaratory relief from the District Court. Further, the Court grants limited stay relief to Mr. Doud to seek direct payment from Hiscox solely under the “Additional Executive Limit of Liability,” set out in Endorsement No. 3 of the Hiscox policy. Finally, the denial of stay relief is without prejudice to Mr. Doud to seek stay relief in the future, after the entry of a final judgment by the District Court in the Hiscox litigation (after time for any appeals have expired, without any appeal having been taken), to seek any proceeds remaining after the satisfaction of any final judgment in

favor of the Debtor.

I. JURISDICTION The Court has jurisdiction under 28 U.S.C. §§ 157 and 1334. This is a core proceeding under 28 U.S.C. § 157(b)(2)(A). Venue is proper under 28 U.S.C. §§ 1408 and 1409.

II. PROCEDURAL POSTURE

On November 17, 2020, Mr. Doud filed a motion seeking an order “authorizing Hiscox to advance Defense Costs” to Mr. Doud. (ECF No. 922 ¶ 10). The motion was made returnable on December 10, 2020. The parties agreed to adjourn the motion several times. (ECF Nos. 956, 1004, 1030). An initial hearing on the motion was held on January 29, 2021, after which the Court ordered the parties to submit memoranda of law in support of their positions. (ECF No. 1186). On February 23, 2021, the parties submitted their memoranda in keeping with the Court’s Order. (ECF Nos. 1238, 1240). After reading the supplemental memoranda of the parties, and having heard oral argument on January 29, 2021, the Court took the motion under submission without the need to hear additional oral argument. (ECF No. 1251). III. FACTS On March 8, 2017, the Debtor obtained a “Private Company Management Liability Insurance Policy” from Hiscox Insurance Company (Policy No. UVA 1901769.17). (ECF Nos. 922 ¶ 6; 948 ¶ 8). The Policy covered a one-year period, ending March 8, 2018. (Id.). Included

among the various coverages is “Directors & Officers Liability Coverage,” and it is that coverage which is at issue here. (ECF No. 948 ¶ 10). As described by the parties, the Policy includes typical side A and side B coverages—side A covering directors and officers for covered losses and side B covering the Debtor in the event it indemnifies a director or officer for such losses. (Id.; see also ECF No. 922 ¶ 7). In the motion, Mr. Doud mentions only the side A and side B coverages under the Policy. However, there is additional entity coverage for the Debtor, in the form of side C and side D coverages—side C covering the Debtor for certain claims and side D covering certain reputational losses by the Debtor. (ECF No. 948 ¶ 10). Mr. Doud seeks stay relief, apparently at the urging of Hiscox, so as to obtain from Hiscox

an “advance [of] Defense Costs” under the side A coverage of the Policy. (ECF No. 922 ¶ 9). As Mr. Doud would have it, under the Order of Payments provision in the Policy, the coverage available for directors and officers (under side A) takes priority over the entity coverage available to the Debtor (under side C). (ECF No. 1240 at 5-10). The Debtor interprets the Order of Payments provision as granting the Debtor “the option of directing Hiscox as to which claims to pay in which order.” (ECF No. 948 at 16 n.6). Therein lies the rub. As interpreted by the Debtor, the Policy would provide the Debtor with entity coverage totaling $6 million. (Id. at ¶ 12). In addition, the Policy provides an additional $1 million in coverage for officers and directors exclusively. (Id.). The total available under the Hiscox Policy, according to the Debtor, is $7 million. (Id.). Doud, on the other hand, argues that the $1 million coverage under the “Additional Executive Limit of Liability” is not available until the $5 million in coverage under sides A, B and C is exhausted. (ECF No. 1240 at 5). Doud reaches that conclusion because Hiscox advised him that is how Hiscox interprets its own Policy. (Id.). Before this chapter 11 case was filed, the Debtor asserted a claim under the Policy for the

entire $6 million in entity coverage. (ECF No. 948 ¶ 16). After initially agreeing to provide the Debtor with coverage, Hiscox subsequently denied coverage under the Policy. (ECF No. 1174 ¶ 9). As a result, the Debtor commenced an action in the District Court for the Western District of New York, demanding payment under the Policy. (ECF No. 948 ¶ 17). The District Court litigation, titled Rochester Drug Co-Operative, Inc. v. Hiscox Insurance Company, Inc., Case No. 20-cv-06025 (W.D.N.Y. filed Jan. 10, 2020), remains pending before Judge Wolford. If the Debtor is successful in the Hiscox litigation, it would recover $6 million of insurance proceeds for the benefit of its creditors. (ECF No. 948 ¶ 20). If Mr. Doud is permitted to draw upon the Policy proceeds, as requested in the lift stay motion, there would be a dollar-for-dollar reduction in the

amount remaining for the Debtor under the Policy. (Id.). Further, if Mr. Doud is permitted to draw on the side A coverage for the $2 million he seeks, Hiscox will avoid $1 million in potential exposure under the Executive Coverage. Simply put, instead of facing potential coverage exposure totaling $7 million, Hiscox would face exposure of $6 million under the sides A, B, C coverage under the Policy. Mr. Doud argues that he will be harmed more grievously than will the Debtor if he is not allowed to immediately access the Hiscox Policy proceeds. Mr. Doud reasons that, as an 80-year- old man facing the potential prison term of 10 years to life (if convicted), the “stakes” are higher than the loss of a couple million dollars by the Debtor’s creditors. (ECF No. 1240 at 10). However, as the Creditors’ Committee counters, if convicted, Mr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Rochester Drug Cooperative, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/rochester-drug-cooperative-inc-nywb-2021.